TY - JOUR
T1 - First-year costs of treating prostate cancer
T2 - Estimates from SEER-Medicare data
AU - Roehrborn, Claus
AU - Albertsen, P.
AU - Stokes, M. E.
AU - Black, L.
AU - Benedict, A.
N1 - Funding Information:
Libby Black is an employee of GSK. Dr. Peter Albertsen is a paid consultant to GSK. Funding for this study was provided by GSK.
Funding Information:
This study used the linked SEER-Medicare database. The interpretation and reporting of these data are the sole responsibility of the authors. The authors acknowledge the efforts of the Applied Research Program, National Cancer Institute; the Office of Research, Development and Information, CMS; Information Management Services, Inc.; and the Surveillance, Epidemiology, and End Results (SEER) Program tumor registries in the creation of the SEER-Medicare database. Research funding was provided by GlaxoSmithKline Inc.
PY - 2009
Y1 - 2009
N2 - Pharmacologic therapies are currently being evaluated for the prevention of prostate cancer (PCa). As additional clinical data become available regarding their benefits and risks, an examination of their economic impact will also be important. The purpose of this study was to estimate mean per patient PCa-related costs during the first year following diagnosis and to examine the extent to which initial therapies are used, by initial cancer stage. Our data show that health-care costs were significant and varied by stage. With average first-year PCa-related costs of US$13091, prevention strategies have the potential to reduce health-care costs.
AB - Pharmacologic therapies are currently being evaluated for the prevention of prostate cancer (PCa). As additional clinical data become available regarding their benefits and risks, an examination of their economic impact will also be important. The purpose of this study was to estimate mean per patient PCa-related costs during the first year following diagnosis and to examine the extent to which initial therapies are used, by initial cancer stage. Our data show that health-care costs were significant and varied by stage. With average first-year PCa-related costs of US$13091, prevention strategies have the potential to reduce health-care costs.
UR - http://www.scopus.com/inward/record.url?scp=70749111420&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70749111420&partnerID=8YFLogxK
U2 - 10.1038/pcan.2009.21
DO - 10.1038/pcan.2009.21
M3 - Article
C2 - 19468284
AN - SCOPUS:70749111420
SN - 1365-7852
VL - 12
SP - 355
EP - 360
JO - Prostate Cancer and Prostatic Diseases
JF - Prostate Cancer and Prostatic Diseases
IS - 4
ER -